Updated on 14 September 2026
Patent-Pending Nanotechnological Platform to Redirect Immune Cells Against Cancer
Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM
Madrid, Spain
About
Our product is a proprietary, patent-pending nanotechnology platform designed to improve cancer immunotherapy by selectively connecting immune cells with tumor cells.
The technology promotes immune cell–tumor interaction and redirects the immune response toward cancer cells, without the need for complex genetic modification of immune cells.
It has the potential to provide a simpler, more versatile and cost-effective approach to immune cell-based therapies, while improving their therapeutic performance. The platform is being developed for oncology applications and has the potential to be adapted to different tumor types and immunotherapeutic strategies.
We are seeking investment and strategic partners to accelerate preclinical development, expand validation and advance toward clinical translation and commercialization.
Stage
- Startup
Applies to
- Biotech, Pharma and Cosmetics
- Healthcare
- Nano- and Microtechnologies
Organisation
Similar opportunities
Partnership
Patent-Pending Nanotechnology Platform for Immune Cell–Tumor Cell Engagement
- Development
Alejandro Baeza García
Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM
Madrid, Spain
Product
GMP Recombinant Cytokines & Growth Factors for Cell & Gene Therapy Manufacturing
- Importer
- Health innovation
- Distribution Partner
- Laboratory industry
- Pharmaceutical industry
俊翰 趙
Business Development manager at Croyez Bioscience
Taipei, Taiwan
Product
Ana Somé
Technology Transfer Manager - Specialist on Intellectual Property at OTRI-Universidad de Malaga
Málaga, Spain